Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RNA aggregates harness the danger response for potent cancer immunotherapy.
Mendez-Gomez HR, DeVries A, Castillo P, von Roemeling C, Qdaisat S, Stover BD, Xie C, Weidert F, Zhao C, Moor R, Liu R, Soni D, Ogando-Rivas E, Chardon-Robles J, McGuiness J, Zhang D, Chung MC, Marconi C, Michel S, Barpujari A, Jobin GW, Thomas N, Ma X, Campaneria Y, Grippin A, Karachi A, Li D, Sahay B, Elliott L, Foster TP, Coleman KE, Milner RJ, Sawyer WG, Ligon JA, Simon E, Cleaver B, Wynne K, Hodik M, Molinaro AM, Guan J, Kellish P, Doty A, Lee JH, Massini T, Kresak JL, Huang J, Hwang EI, Kline C, Carrera-Justiz S, Rahman M, Gatica S, Mueller S, Prados M, Ghiaseddin AP, Silver NL, Mitchell DA, Sayour EJ. Mendez-Gomez HR, et al. Among authors: silver nl. Cell. 2024 May 9;187(10):2521-2535.e21. doi: 10.1016/j.cell.2024.04.003. Epub 2024 May 1. Cell. 2024. PMID: 38697107
mRNA aggregates harness danger response for potent cancer immunotherapy.
Mendez-Gomez HR, DeVries A, Castillo P, Stover BD, Qdaisat S, Von Roemeling C, Ogando-Rivas E, Weidert F, McGuiness J, Zhang D, Chung MC, Li D, Zhang C, Marconi C, Campaneria Y, Chardon-Robles J, Grippin A, Karachi A, Thomas N, Huang J, Milner R, Sahay B, Sawyer WG, Ligon JA, Silver N, Simon E, Cleaver B, Wynne K, Hodik M, Molinaro A, Guan J, Kellish P, Doty A, Lee JH, Carrera-Justiz S, Rahman M, Gatica S, Mueller S, Prados M, Ghiaseddin A, Mitchell DA, Sayour EJ. Mendez-Gomez HR, et al. medRxiv [Preprint]. 2023 Mar 17:2023.03.12.23287108. doi: 10.1101/2023.03.12.23287108. medRxiv. 2023. Update in: Cell. 2024 May 9;187(10):2521-2535.e21. doi: 10.1016/j.cell.2024.04.003. PMID: 36993772 Free PMC article. Updated. Preprint.
mRNA challenge predicts brain cancer immunogenicity and response to checkpoint inhibitors.
Castillo P, Ogando-Rivas E, Geffrard H, Pepe A, Liu R, Nguyen DT, Pedro DI, Zhang D, DeVries A, Qdaisat S, Karachi A, Rahman M, Weidert F, Milner R, Huang J, Silver NL, Ligon J, Li D, Lee JH, Carrera-Justiz S, Mitchell DA, Mendez-Gomez H, Sawyer WG, Sayour EJ. Castillo P, et al. Among authors: silver nl. bioRxiv [Preprint]. 2023 Mar 23:2023.03.18.532056. doi: 10.1101/2023.03.18.532056. bioRxiv. 2023. PMID: 36993158 Free PMC article. Preprint.
Immunotherapy response in patients with cutaneous squamous cell carcinoma of head and neck with cranial nerve involvement.
Lopetegui-Lia N, Dima D, Buchberger DS, Yalamanchali A, Osantowski B, Ondeck M, Lorenz RR, Prendes B, Ku J, Lamarre E, Scharpf J, Silver NL, Schwartzman L, Geiger JL, Woody NM, Campbell SR, Koyfman SA, Yilmaz E. Lopetegui-Lia N, et al. Among authors: silver nl. Head Neck. 2023 Aug;45(8):2149-2154. doi: 10.1002/hed.27419. Epub 2023 Jun 5. Head Neck. 2023. PMID: 37272705
Clinical outcomes of combined cervical and transthoracic surgical approaches in patients with advanced thyroid cancer.
Shenson JA, Zafereo ME, Lee M, Contrera KJ, Feng L, Boonsripitayanon M, Gross N, Goepfert R, Maniakas A, Wang JR, Grubbs L, Vaporciyan A, Hofstetter W, Swisher S, Mehran R, Rice D, Sepesi B, Antonoff M, Cabanillas M, Busaidy N, Dadu R, Silver NL. Shenson JA, et al. Among authors: silver nl. Head Neck. 2023 Mar;45(3):547-554. doi: 10.1002/hed.27260. Epub 2022 Dec 16. Head Neck. 2023. PMID: 36524701
Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234.
Michikawa C, Torres-Saavedra PA, Silver NL, Harari PM, Kies MS, Rosenthal DI, Le QT, Jordan RC, Duose DY, Mallampati S, Trivedi S, Luthra R, Wistuba II, Osman AA, Lichtarge O, Foote RL, Parvathaneni U, Hayes DN, Pickering CR, Myers JN. Michikawa C, et al. Among authors: silver nl. Adv Radiat Oncol. 2022 May 18;7(6):100989. doi: 10.1016/j.adro.2022.100989. eCollection 2022 Nov-Dec. Adv Radiat Oncol. 2022. PMID: 36420184 Free PMC article.
28 results